Gayen Shameek K, Baughman Robert P, Nathan Steven D, Wells Athol U, Kouranos Vasilis, Alhamad Esam H, Culver Daniel A, Barney Joseph, Carmoma Eva M, Cordova Francis C, Huitema Marloes, Scholand Mary Beth, Wijsenbeek Marlies, Ganesh Sivagini, Birring Surinder S, Price Laura C, Wort Stephen J, Shlobin Oksana A, Gupta Rohit
Department of Thoracic Medicine and Surgery Lewis Katz School of Medicine at Temple University Hospital Philadelphia Pennsylvania USA.
Department of Medicine University of Cincinnati Medical Center Cincinnati Ohio USA.
Pulm Circ. 2023 Oct 11;13(4):e12297. doi: 10.1002/pul2.12297. eCollection 2023 Oct.
Pulmonary hypertension (PH) is a risk factor for mortality in patients with sarcoidosis. Severe PH in chronic lung disease has previously been defined as mean pulmonary arterial pressure (mPAP) ≥ 35 mmHg or mPAP 25 ≥ mmHg with cardiac index (CI) ≤ 2 L/min/m. However, there is no clear definition denoting severity of sarcoidosis-associated PH (SAPH). We aimed to determine pulmonary hemodynamic cut-off values where transplant-free survival was worse among patients with SAPH. This was a retrospective cohort analysis of the Registry of SAPH database focusing on pulmonary hemodynamic predictors of transplant-free survival among patients with precapillary SAPH. Cox regression was performed to determine which pulmonary hemodynamic values predicted death or lung transplantation. Kaplan-Meier survival analysis was performed on statistically significant predictors to determine pulmonary hemodynamic cut-off values where transplant-free survival was decreased. Decreased transplant-free survival occurred among SAPH patients with mPAP ≥ 40 mmHg and SAPH patients with pulmonary vascular resistance (PVR) ≥ 5 Woods units (WU). Transplant-free survival was not decreased in patients who fulfilled prior criteria of severe PH in chronic lung disease. We identified new cut-offs with decreased transplant-free survival in the SAPH population. Neither cut-off of mPAP ≥ 40 mmHg nor PVR ≥ 5 WU has previously been shown to be associated with decreased transplant-free survival in SAPH. These values could suggest a new definition of severe SAPH. Our PVR findings are in line with the most recent European Society of Cardiology/European Respiratory Society guideline definition of severe PH in chronic lung disease.
肺动脉高压(PH)是结节病患者死亡的一个危险因素。慢性肺病中的重度PH此前被定义为平均肺动脉压(mPAP)≥35 mmHg或mPAP 25≥mmHg且心脏指数(CI)≤2 L/min/m²。然而,尚无明确的定义来表示结节病相关PH(SAPH)的严重程度。我们旨在确定在SAPH患者中无移植生存期较差时的肺血流动力学临界值。这是一项对SAPH数据库注册研究的回顾性队列分析,重点关注毛细血管前性SAPH患者无移植生存期的肺血流动力学预测因素。进行Cox回归以确定哪些肺血流动力学值可预测死亡或肺移植。对具有统计学意义的预测因素进行Kaplan-Meier生存分析,以确定无移植生存期降低时的肺血流动力学临界值。mPAP≥40 mmHg的SAPH患者和肺血管阻力(PVR)≥5伍兹单位(WU)的SAPH患者的无移植生存期降低。符合慢性肺病中重度PH既往标准的患者,其无移植生存期并未降低。我们在SAPH人群中确定了无移植生存期降低的新临界值。此前尚未证明mPAP≥40 mmHg或PVR≥5 WU的临界值与SAPH患者无移植生存期降低相关。这些值可能提示重度SAPH的新定义。我们关于PVR的研究结果与欧洲心脏病学会/欧洲呼吸学会关于慢性肺病中重度PH的最新指南定义一致。